Last reviewed · How we verify

Geropharm — Portfolio Competitive Intelligence Brief

Geropharm pipeline: 2 marketed, 0 filed, 9 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 9 Phase 3 0 Phase 2 12 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Apidra® SoloStar® Apidra® SoloStar® marketed
Prezista® Prezista® marketed HIV protease inhibitor HIV protease Infectious Disease
GP404141 GP404141 phase 3 S1P receptor modulator S1P receptor Immunology
Insulin Humulin® NPH Insulin Humulin® NPH phase 3 Intermediate-acting human insulin Insulin receptor (IR) Diabetes
GP40321 GP40321 phase 3 Serotonin receptor antagonist 5-HT2A receptor Psychiatry
RinGlar® RinGlar® phase 3 GLP-1 receptor agonist GLP-1R Diabetes
GP40071 GP40071 phase 3 ACE inhibitor ACE Cardiovascular
Insulin Lispro Biphasic 25 Insulin Lispro Biphasic 25 phase 3 Premixed insulin (rapid-acting + intermediate-acting) Insulin receptor Diabetes
NovoRapid® Penfill® NovoRapid® Penfill® phase 3 Rapid-acting insulin analog Insulin receptor Diabetes
Insulin Rinsulin® NPH Insulin Rinsulin® NPH phase 3 Intermediate-acting insulin Insulin receptor Diabetes
GP40081 GP40081 phase 3 sigma-1 receptor modulator sigma-1 receptor Neurology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. GlaxoSmithKline · 4 shared drug classes
  2. Sanofi · 4 shared drug classes
  3. Eli Lilly and Company · 3 shared drug classes
  4. Novo Nordisk A/S · 3 shared drug classes
  5. Rigshospitalet, Denmark · 2 shared drug classes
  6. Takeda · 2 shared drug classes
  7. Phytopharm Consulting Brazil · 2 shared drug classes
  8. Aclaris Therapeutics, Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Geropharm:

Cite this brief

Drug Landscape (2026). Geropharm — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/geropharm. Accessed 2026-05-13.

Related